A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.
Huang WT, Chen HH, Yeh CH, Lu YC, Hwang WS, Huang JS, Chen CP, Lin PC, Uen WC, Lee YC, Wang HM, Wu HC, Chen JS, Kao RH, Huang CC, Jeng HH, Lin CJ, Hsieh RK.
Huang WT, et al. Among authors: huang cc, huang js.
J Investig Med. 2013 Oct;61(7):1108-14. doi: 10.2310/JIM.0b013e3182a6799d.
J Investig Med. 2013.
PMID: 24013526